Photoactivated gamma-secretase inhibitors directed to the active site covalently label presenilin 1
- PMID: 10864326
- DOI: 10.1038/35015085
Photoactivated gamma-secretase inhibitors directed to the active site covalently label presenilin 1
Abstract
Cleavage of amyloid precursor protein (APP) by the beta- and gamma-secretases generates the amino and carboxy termini, respectively, of the A beta amyloidogenic peptides A beta40 and A beta42--the major constituents of the amyloid plaques in the brain parenchyma of Alzheimer's disease patients. There is evidence that the polytopic membrane-spanning proteins, presenilin 1 and 2 (PS1 and PS2), are important determinants of gamma-secretase activity: mutations in PS1 and PS2 that are associated with early-onset familial Alzheimer's disease increase the production of A beta42 (refs 4-6), the more amyloidogenic peptide; gamma-secretase activity is reduced in neuronal cultures derived from PS1-deficient mouse embryos; and directed mutagenesis of two conserved aspartates in transmembrane segments of PS1 inactivates the ability of gamma-secretase to catalyse processing of APP within its transmembrane domain. It is unknown, however, whether PS1 (which has little or no homology to any known aspartyl protease) is itself a transmembrane aspartyl protease or a gamma-secretase cofactor, or helps to colocalize gamma-secretase and APP. Here we report photoaffinity labelling of PS1 (and PS2) by potent gamma-secretase inhibitors that were designed to function as transition state analogue inhibitors directed to the active site of an aspartyl protease. This observation indicates that PS1 (and PS2) may contain the active site of gamma-secretase. Interestingly, the intact, single-chain form of wild-type PS1 is not labelled by an active-site-directed photoaffinity probe, suggesting that intact wild-type PS1 may be an aspartyl protease zymogen.
Similar articles
-
FAD mutations in presenilin-1 or amyloid precursor protein decrease the efficacy of a gamma-secretase inhibitor: evidence for direct involvement of PS1 in the gamma-secretase cleavage complex.Neurobiol Dis. 2000 Dec;7(6 Pt B):673-81. doi: 10.1006/nbdi.2000.0322. Neurobiol Dis. 2000. PMID: 11114265
-
Two transmembrane aspartates in presenilin-1 required for presenilin endoproteolysis and gamma-secretase activity.Nature. 1999 Apr 8;398(6727):513-7. doi: 10.1038/19077. Nature. 1999. PMID: 10206644
-
Presenilin clinical mutations can affect gamma-secretase activity by different mechanisms.J Neurochem. 2006 Feb;96(3):732-42. doi: 10.1111/j.1471-4159.2005.03578.x. Epub 2006 Jan 9. J Neurochem. 2006. PMID: 16405513
-
The Alzheimer's disease-associated gamma-secretase complex: functional domains in the presenilin 1 protein.Physiol Behav. 2007 Sep 10;92(1-2):115-20. doi: 10.1016/j.physbeh.2007.05.037. Epub 2007 May 21. Physiol Behav. 2007. PMID: 17588625 Review.
-
Are presenilins intramembrane-cleaving proteases? Implications for the molecular mechanism of Alzheimer's disease.Biochemistry. 1999 Aug 31;38(35):11223-30. doi: 10.1021/bi991080q. Biochemistry. 1999. PMID: 10471271 Review.
Cited by
-
Transmembrane Substrate Determinants for γ-Secretase Processing of APP CTFβ.Biochemistry. 2016 Oct 11;55(40):5675-5688. doi: 10.1021/acs.biochem.6b00718. Epub 2016 Sep 30. Biochemistry. 2016. PMID: 27649271 Free PMC article.
-
New precision medicine avenues to the prevention of Alzheimer's disease from insights into the structure and function of γ-secretases.EMBO J. 2024 Mar;43(6):887-903. doi: 10.1038/s44318-024-00057-w. Epub 2024 Feb 23. EMBO J. 2024. PMID: 38396302 Free PMC article. Review.
-
The innate immunity protein IFITM3 modulates γ-secretase in Alzheimer's disease.Nature. 2020 Oct;586(7831):735-740. doi: 10.1038/s41586-020-2681-2. Epub 2020 Sep 2. Nature. 2020. PMID: 32879487 Free PMC article.
-
New approaches for dissecting protease functions to improve probe development and drug discovery.Nat Struct Mol Biol. 2012 Jan 5;19(1):9-16. doi: 10.1038/nsmb.2203. Nat Struct Mol Biol. 2012. PMID: 22218294 Free PMC article. Review.
-
Notch signaling pathway: architecture, disease, and therapeutics.Signal Transduct Target Ther. 2022 Mar 24;7(1):95. doi: 10.1038/s41392-022-00934-y. Signal Transduct Target Ther. 2022. PMID: 35332121 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources